TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32805144

Group type: EXPERIMENTAL
Intervention: Jatropha curcas with compost amendments
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vetiveria zizanioides with compost amendments
Number of subjects: 3

Group type: COMPARATOR
Intervention: Compost amendments
Number of subjects: 3

Group type: COMPARATOR
Intervention: Contaminated soils
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Soil amendments
Number of subjects: 3
Study: 35251715

Group type: EXPERIMENTAL
Intervention: Maze control training in addition to selected conventional physical therapy
Number of subjects: 30
Study: 34412897

Group type: EXPERIMENTAL
Intervention: Additional light curing after finishing and polishing
Number of subjects: 80

Group type: COMPARATOR
Intervention: No polishing (nonpolished)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polishing with aluminum oxide discs (polished)
Number of subjects: 80
Study: 32888454

Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide (six cycles of intravenous carboplatin [AUC 5 mg/mL per min] on day 1 plus intravenous etoposide [100 mg/m2 from day 1 to day 3])
Number of subjects: 164

Group type: COMPARATOR
Intervention: Topotecan (2.3 mg/m2 from day 1 to day 5, for six cycles)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide
Number of subjects: 164
Study: 33078917

Group type: EXPERIMENTAL
Intervention: Low-intensity direct current (LIDC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 32
Study: 33043659

Group type: EXPERIMENTAL
Intervention: OPCAB + MVR
Number of subjects: 53

Group type: COMPARATOR
Intervention: ONCAB + MVR
Number of subjects: 53
Study: 34968693

Group type: EXPERIMENTAL
Intervention: BIO-RSA
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metal-augmented baseplates
Number of subjects: 41
Study: 33618124

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT) with low working memory load (WML)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT) with high working memory load (WML)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT) with no working memory load (WML)
Number of subjects: 306
Study: 32986176

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg/12 h or 2.5 mg/12 h (after dose adjustment or in high-risk patients)
Number of subjects: 160

Group type: COMPARATOR
Intervention: DAPT with aspirin and clopidogrel
Number of subjects: 160
Study: 35487099

Group type: EXPERIMENTAL
Intervention: Neutral hand orientation with directional feedback
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pronated hand orientation with directional feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aiming errors without feedback
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aiming errors with feedback
Number of subjects: 30
Study: 33228726

Group type: EXPERIMENTAL
Intervention: losartan potassium plus Keluoxin capsule (KLX)
Number of subjects: 252

Group type: COMPARATOR
Intervention: losartan potassium plus placebo
Number of subjects: 252
Study: 34480868

Group type: EXPERIMENTAL
Intervention: ERP (Exposure and Response Prevention)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Psychoeducation (active control)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: ERP
Number of subjects: 224

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 224
Study: 32925743

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 1000 mg in 100 mL normal saline, administered intravenously over 20 minutes before skin incision
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 80
Study: 36180134

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 33246887

Group type: EXPERIMENTAL
Intervention: olesoxime
Number of subjects: 0
Study: 35658024

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539
Study: 32966877

Group type: EXPERIMENTAL
Intervention: GWL Pack featuring 1 of 3 rotating images added to blank pack
Number of subjects: 359

Group type: COMPARATOR
Intervention: Blank Pack devoid of any cigarette branding
Number of subjects: 359

Group type: COMPARATOR
Intervention: Standard US Pack
Number of subjects: 359
Study: 35650562

Group type: EXPERIMENTAL
Intervention: Peer worker role
Number of subjects: 32
Study: 33678522

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV plus Bevacizumab 15 mg/kg IV every 3 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sunitinib monotherapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Atezolizumab monotherapy
Number of subjects: 103
Study: 32530550

Group type: EXPERIMENTAL
Intervention: Candida antigen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PPD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MMR
Number of subjects: 120
Study: 34487440

Group type: EXPERIMENTAL
Intervention: Pharmacologic cardioversion before electrical cardioversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 0
Study: 32394219

Group type: EXPERIMENTAL
Intervention: ACT-based face-to-face (n=65; six group sessions led by a psychologist)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: ACT-based mobile (n=73; one group session and mobile app)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control (n=66; only the measurements)
Number of subjects: 204
Study: 35436230

Group type: EXPERIMENTAL
Intervention: USSD-based app
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no SRH information)
Number of subjects: 300
Study: 34251103

Group type: EXPERIMENTAL
Intervention: Longidaza (rectal suppositories of 3000 IU)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (standard postoperative therapy with tamsulosin and fluoroquinolone)
Number of subjects: 202
Study: 32862662

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 398

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 398
Study: 35906579

Group type: EXPERIMENTAL
Intervention: Home-based or partly supervised exercise programme lasting 2–3 months
Number of subjects: 79
Study: 33177434

Group type: EXPERIMENTAL
Intervention: Nurse-delivered cognitive behavioral intervention (CBI) for 10 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine follow-up (Control)
Number of subjects: 140
Study: 32883033

Group type: EXPERIMENTAL
Intervention: Animal-derived protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant-derived protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen-derived protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blended dietary proteins (animal, plant, collagen)
Number of subjects: 0
Study: 35045820

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Childbirth and Parenting (MBCP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Enhanced care as usual (ECAU)
Number of subjects: 111
Study: 616886749

Group type: EXPERIMENTAL
Intervention: Compound azintamide enteric‐coated tablets
Number of subjects: 90

Group type: COMPARATOR
Intervention: Compound digestive enzyme capsules
Number of subjects: 90
Study: 35535490

Group type: EXPERIMENTAL
Intervention: Digital storytelling‐legacy intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 150
Study: 33369909

Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 4.0
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Leu/Sil 4.0
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0 in African Americans
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0 in participants with BMI <40 kg/m2
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0 in participants with baseline insulin ≥12mU/L
Number of subjects: 267
Study: 32706658

Group type: EXPERIMENTAL
Intervention: HUS‐iCBT plus add‐on scheduled telephone support (STS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: HUS‐iCBT as usual (control group)
Number of subjects: 100
Study: 34789403

Group type: EXPERIMENTAL
Intervention: ap1gen (low-dose recombinant pertussis-only vaccine containing 1 μg PTgen and 1 μg FHA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tdap1gen (tetanus, reduced-dose diphtheria combined to ap1gen)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tdap2gen (combined to recombinant pertussis containing 2 μg PTgen and 5 μg FHA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: TdaP5gen (licensed recombinant TdaP vaccine containing 5 μg PTgen and 5 μg FHA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tdap8chem (licensed Tdap vaccine containing 8 μg of chemically inactivated pertussis toxoid, 8 μg FHA, and 2.5 μg pertactin)
Number of subjects: 250
Study: 34160577

Group type: EXPERIMENTAL
Intervention: NCRT plus surgery
Number of subjects: 451

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 451
Study: 34904247

Group type: EXPERIMENTAL
Intervention: GIC (Equia Forte® ‐ GC Corp)
Number of subjects: 182

Group type: COMPARATOR
Intervention: GCR (Beautifil Bulk Restorative® ‐ Shofu Inc)
Number of subjects: 182
Study: 34536187

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 1983
Study: 33806809

Group type: EXPERIMENTAL
Intervention: Pulse reproductive health app
Number of subjects: 1013

Group type: COMPARATOR
Intervention: General health control app
Number of subjects: 1013
Study: 32679238

Group type: EXPERIMENTAL
Intervention: CPAP treatment plus usual care
Number of subjects: 2687

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2687
Study: 35343648

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 once-a-week with radiotherapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 once every-3-weeks with radiotherapy
Number of subjects: 300
Study: 34059488

Group type: EXPERIMENTAL
Intervention: lenalidomide treatment
Number of subjects: 3894
Study: 36496358

Group type: EXPERIMENTAL
Intervention: Instagram-based vaping cessation intervention (up to 3 posts per weekday for 25 days over 5 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group directed to kickitca.org (website offering cessation services)
Number of subjects: 0
Study: 34533786

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32532291

Group type: EXPERIMENTAL
Intervention: Enadenotucirev (EnAd) in combination with chemoradiotherapy
Number of subjects: 30
Study: 36422808

Group type: EXPERIMENTAL
Intervention: Levotiroxina MK® (test product)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 80
Study: 34453840

Group type: EXPERIMENTAL
Intervention: Ablation + CRT
Number of subjects: 133

Group type: COMPARATOR
Intervention: Drug (pharmacological rate control)
Number of subjects: 133
Study: 33520069

Group type: EXPERIMENTAL
Intervention: Susceptibility to smoke cigarettes
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Future intention to smoke cigarettes
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Predictors of susceptibility
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Predictors of future intention to smoke
Number of subjects: 830
Study: 35119113

Group type: EXPERIMENTAL
Intervention: Solution-focused psychoeducation (SFP)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Childbirth preparation training (CPT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group care
Number of subjects: 119
Study: 34381612

Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Thermal Radiofrequency (RF)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 69
Study: 32491964

Group type: EXPERIMENTAL
Intervention: Michigan occlusal splint (G1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (G2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: LLLT placebo (G3)
Number of subjects: 30
Study: 32741710

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with core decompression (CD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Core decompression (CD) only
Number of subjects: 40
Study: 34184823

Group type: EXPERIMENTAL
Intervention: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Number of subjects: 71000
Study: 32955801

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine prophylaxis
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Randomized clinical trial (RCT)
Number of subjects: 785
Study: 34802083

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (LAH)
Number of subjects: 4039
Study: 34535959

Group type: EXPERIMENTAL
Intervention: Glycine supplementation (7 g twice daily for 4 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (7 g twice daily for 4 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison of glycine and BCAA
Number of subjects: 27
Study: 36494793

Group type: EXPERIMENTAL
Intervention: Endometrial microstimulation (EM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 33723086

Group type: EXPERIMENTAL
Intervention: Axxess bifurcation device (Biosensors) in combination with Absorb BVS (Abbott Vascular)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Modified-T strategy using Absorb BVS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 33364598

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 42

Group type: COMPARATOR
Intervention: non-efavirenz
Number of subjects: 42
Study: 34155957

Group type: EXPERIMENTAL
Intervention: Classical double-layer uterine closure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Purse-string double-layer uterine closure (Turan)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Double layer step up-step down technique
Number of subjects: 120
Study: 34099322

Group type: EXPERIMENTAL
Intervention: StrataGraft
Number of subjects: 71

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 71
Study: 32431162

Group type: EXPERIMENTAL
Intervention: TeachTown:Basics
Number of subjects: 0

Group type: COMPARATOR
Intervention: No access to TeachTown:Basics (Control)
Number of subjects: 0
Study: 35704479

Group type: EXPERIMENTAL
Intervention: HSIL treatment (including office-based ablative procedures, ablation or excision under anesthesia, or topical fluorouracil or imiquimod)
Number of subjects: 4446

Group type: COMPARATOR
Intervention: Active monitoring without treatment
Number of subjects: 4446
Study: 32700955

Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Inhibitory Control Training (ICT)
Number of subjects: 54
Study: 36373654

Group type: EXPERIMENTAL
Intervention: LAAE
Number of subjects: 562

Group type: COMPARATOR
Intervention: No LAAE
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: OAC
Number of subjects: 562
Study: 33210771

Group type: EXPERIMENTAL
Intervention: Early loading protocol (test group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional loading protocol (control group)
Number of subjects: 34
Study: 36031439

Group type: EXPERIMENTAL
Intervention: TXA (10 mg/kg bolus dose 15 min prior to incision and another similar dose after 3 h)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (normal saline, same volume as TXA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: TXA
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 34063276

Group type: EXPERIMENTAL
Intervention: Probiotics stimulation (SG)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 69
Study: 35212877

Group type: EXPERIMENTAL
Intervention: Text message-based communication intervention
Number of subjects: 100
Study: 33388990

Group type: EXPERIMENTAL
Intervention: Primary site surgery
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Radiation
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 923
Study: 34332332

Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Final models
Number of subjects: 147
Study: 35381164

Group type: EXPERIMENTAL
Intervention: Busulfan, Melphalan, and Etoposide (BuME)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Busulfan, Cyclophosphamide, and Etoposide (BuCE)
Number of subjects: 75
Study: 33515972

Group type: EXPERIMENTAL
Intervention: Birth choice decision aid booklet
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (general maternal health booklet)
Number of subjects: 65
Study: 35909585

Group type: EXPERIMENTAL
Intervention: Traditional breathing therapy (TG)
Number of subjects: 40
Study: 32720582

Group type: EXPERIMENTAL
Intervention: High-intensity statin, ezetimibe, and high-dose proprotein convertase subtilisin/kexin type 9 inhibitor
Number of subjects: 22

Group type: COMPARATOR
Intervention: New time-dependent model
Number of subjects: 22
Study: 35082351

Group type: EXPERIMENTAL
Intervention: Physical-possession condition (participants possessed a tangible placebo analgesic oil)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Psychological-possession condition (participants possessed a coupon for a placebo analgesic oil)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No-possession condition
Number of subjects: 90
Study: 33878835

Group type: EXPERIMENTAL
Intervention: Modified posteromedial approach via lateral side of flexor hallucis longus
Number of subjects: 43

Group type: COMPARATOR
Intervention: Modified posteromedial approach
Number of subjects: 43
Study: 35452261

Group type: EXPERIMENTAL
Intervention: Language intervention with a peer with typically developing language (TDL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Language intervention with a peer with developmental language disorder (DLD)
Number of subjects: 20
Study: 33548329

Group type: EXPERIMENTAL
Intervention: Combination of 0.5 mg dexamethasone and 800 mg ibuprofen
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0.5 mg dexamethasone
Number of subjects: 94

Group type: COMPARATOR
Intervention: 800 mg ibuprofen
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 33164611

Group type: EXPERIMENTAL
Intervention: Upadacitinib 7.5 mg daily
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg daily
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg daily
Number of subjects: 138

Group type: COMPARATOR
Intervention: Methotrexate 7.5 mg/week (titrated to ≤15 mg/week)
Number of subjects: 138
Study: 33381165

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 30

Group type: COMPARATOR
Intervention: staVNS
Number of subjects: 30
Study: 36148320

Group type: EXPERIMENTAL
Intervention: 3 μg/(kg·min) mivacurium (group M1)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 6 μg/(kg·min) mivacurium (group M2)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 9 μg/(kg·min) mivacurium (group M3)
Number of subjects: 99
Study: 33668062

Group type: EXPERIMENTAL
Intervention: Diet with 100% of the choline AI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet with 50% of the choline AI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet with 25% of the choline AI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRS analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MS analysis of plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma betaine concentrations
Number of subjects: 0
Study: 32381105

Group type: EXPERIMENTAL
Intervention: Simulation educational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital didactic environment educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33992088

Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs
Number of subjects: 833

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 833
Study: 32609847

Group type: EXPERIMENTAL
Intervention: HR-E (cutting-out the easiest cigarettes first)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: HR-D (cutting-out the most difficult cigarettes first)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: SFP (not smoking during particular periods)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: SR (smoking on an increasing time schedule)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Gradual cessation methods (overall)
Number of subjects: 342
Study: 35904950

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy followed by laser therapy (980 nm DL, 1 W, continuous wave mode, 20 sec per tooth side, repeated twice at 5‐7 day intervals)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonsurgical periodontal therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy followed by laser therapy
Number of subjects: 36
Study: 32412917

Group type: EXPERIMENTAL
Intervention: Prescription Tongxin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Shexiang Baoxin Pill
Number of subjects: 48
Study: 32484850

Group type: EXPERIMENTAL
Intervention: SENATOR software-guided medication optimization plus standard care
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1537
Study: 35638918

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 190
Study: 33542551

Group type: EXPERIMENTAL
Intervention: Partial cystectomy and adjunctive medical therapy (Group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medical therapy alone (Group B)
Number of subjects: 47
Study: 32074624

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) + Treatment as Usual (TAU)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Specialized Attention Therapy (SAT) + Treatment as Usual (TAU)
Number of subjects: 132